Results
|
|
1.
|
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(14):1427-36, 2014 May 10.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Ales-Martinez JE, Brundage M, Cheung AM, Chlebowski RT, Cooke AL, Dube P, Ellard SL, Fabian CJ, Gelmon KA, Goss PE, Hendrix S, Hiltz A, Ingle JN, Johnston D, Lickley L, Maunsell E, Pater JL, Pruthi S, Pujol P, Richardson H, Rowland KM, Ruiz A, Sarto GE, Spadafora S, Thayer DW, Tu D, Wactawski-Wende J
|
|
|
2.
|
|
|
|
3.
|
|
|
|
4.
|
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. MedStar authors:
Year: 2019
Citation: - Lancet Oncology. 20(1):88-99, 2019 01.
Institution: - MedStar Franklin Square Medical Center
Medline publication type:
All authors: - Bandos H, Brufsky AM, Chia SK, Dakhil SR, Fehrenbacher L, Geyer CE Jr, Graham ML, Jeong JH, Lembersky BC, Mamounas EP, McCarron EC, Paik S, Rastogi P, Seay TE, Soori GS, Swain SM, Wade JL 3rd, Walshe JM, Wickerham DL, Wolmark N
|
